IRON
Disc Medicine, Inc.
Price Chart
Latest Quote
$70.25
-0.09 (-0.12%)
Current Price
| Previous Close | $70.34 |
| Open | $70.39 |
| Day High | $71.78 |
| Day Low | $69.97 |
| Volume | 170,794 |
Stock Information
| Shares Outstanding | 38.20M |
| Total Debt | $31.06M |
| Cash Equivalents | $730.16M |
| Net Income | $-241.60M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.68B |
| EPS (TTM) | $-6.64 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.99B |
| Income | $-241.60M |
| Book/sh | $18.03 |
| Cash/sh | $19.11 |
| Employees | 154 |
Financial Ratios
| Quick Ratio | 23.45 |
| Current Ratio | 24.00 |
| Debt/Eq | 4.51 |
Returns & Margins
| ROA | -22.67% |
| ROE | -35.83% |
Ownership
| Insider Ownership | 7.78% |
| Institutional Ownership | 113.72% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -9.25 |
| P/B | 3.89 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $101.55 |
Technical Indicators
| SMA20 | $69.45 |
| SMA50 | $68.73 |
| SMA200 | $73.35 |
| RSI | 46.57 |
| ATR | 2.8909 |
| Shares Float | 32.75M |
| Short Float | 18.33% |
| Short Ratio | 12.35 |
| Volatility | 2.10 |
| Rel Volume | 1.61 |
Performance History
| Week | -0.07% |
| Month | +2.99% |
| Quarter | +12.17% |
| 6 Months | -11.79% |
| YTD | -11.29% |
| Year | +27.56% |
| 3 Years | +32.43% |
| 5 Years | -78.95% |
| 10 Years | -77.29% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $70.16 | 927,948 |
| 2026-06-24 | $70.37 | 1,220,500 |
| 2026-06-23 | $70.45 | 537,200 |
| 2026-06-22 | $70.80 | 707,800 |
| 2026-06-18 | $70.79 | 1,562,300 |
| 2026-06-17 | $70.21 | 692,500 |
| 2026-06-16 | $69.83 | 339,400 |
| 2026-06-15 | $70.09 | 464,100 |
| 2026-06-12 | $67.99 | 184,500 |
| 2026-06-11 | $68.08 | 219,600 |
| 2026-06-10 | $67.25 | 271,600 |
| 2026-06-09 | $68.34 | 590,200 |
| 2026-06-08 | $65.80 | 711,500 |
| 2026-06-05 | $67.00 | 454,500 |
| 2026-06-04 | $71.11 | 469,200 |
| 2026-06-03 | $70.35 | 335,600 |
| 2026-06-02 | $68.00 | 415,500 |
| 2026-06-01 | $71.97 | 636,500 |
| 2026-05-29 | $69.57 | 360,900 |
| 2026-05-28 | $70.80 | 420,800 |
| 2026-05-27 | $69.76 | 333,400 |
| 2026-05-26 | $68.12 | 230,600 |
About Disc Medicine, Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
đ° Latest News
How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients
Simply Wall St. âĸ 2026-06-01T14:07:16Z
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges
MarketBeat âĸ 2026-05-26T04:04:52Z
A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter
Simply Wall St. âĸ 2026-05-06T22:14:48Z
Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge
Motley Fool âĸ 2026-04-21T17:13:09Z
Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals
Simply Wall St. âĸ 2026-03-11T00:18:14Z
What 3 recent FDA rejections reveal about shifts inside the agency
Pharma Voice âĸ 2026-03-04T07:55:52Z
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection
Motley Fool âĸ 2026-03-01T19:30:00Z
Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf Registration - What's Changed
Simply Wall St. âĸ 2026-02-28T15:11:04Z
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction
Motley Fool âĸ 2026-02-25T20:39:41Z
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
Motley Fool âĸ 2026-02-25T20:26:18Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $3,607,000 | $572,000 | $0 | - |
| Total Expenses | $236,022,000 | $129,720,000 | $91,125,000 | $47,475,000 |
| Other Income Expense | $45,000 | $-2,000 | $-2,000 | $-61,000 |
| Other Non Operating Income Expenses | $45,000 | $-2,000 | $-2,000 | - |
| Net Non Operating Interest Income Expense | $24,154,000 | $20,720,000 | $14,797,000 | $709,000 |
| Interest Expense Non Operating | $3,607,000 | $572,000 | $0 | - |
| Operating Expense | $236,022,000 | $129,720,000 | $91,125,000 | $47,475,000 |
| General And Administrative Expense | $65,382,000 | $33,049,000 | $21,861,000 | $14,038,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-212,184,000 | $-109,357,000 | $-76,429,000 | $-46,827,000 |
| Net Interest Income | $24,154,000 | $20,720,000 | $14,797,000 | $709,000 |
| Interest Income | $27,761,000 | $21,292,000 | $14,797,000 | $709,000 |
| Normalized Income | $-212,184,000 | $-109,357,000 | $-76,429,000 | $-46,766,000 |
| Net Income From Continuing And Discontinued Operation | $-212,184,000 | $-109,357,000 | $-76,429,000 | $-46,827,000 |
| Total Operating Income As Reported | $-236,022,000 | $-129,720,000 | $-91,125,000 | $-47,475,000 |
| Net Income Common Stockholders | $-212,184,000 | $-109,357,000 | $-76,429,000 | $-46,827,000 |
| Net Income | $-212,184,000 | $-109,357,000 | $-76,429,000 | $-46,827,000 |
| Net Income Including Noncontrolling Interests | $-212,184,000 | $-109,357,000 | $-76,429,000 | $-46,827,000 |
| Net Income Continuous Operations | $-212,184,000 | $-109,357,000 | $-76,429,000 | $-46,827,000 |
| Pretax Income | $-211,823,000 | $-109,002,000 | $-76,330,000 | $-46,827,000 |
| Interest Income Non Operating | $27,761,000 | $21,292,000 | $14,797,000 | $709,000 |
| Operating Income | $-236,022,000 | $-129,720,000 | $-91,125,000 | $-47,475,000 |
| Per Share | ||||
| Diluted EPS | $-6.01 | $-3.96 | $-3.42 | $-45.05 |
| Basic EPS | $-6.01 | $-3.96 | $-3.42 | $-45.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-207,935,000 | $-108,274,000 | $-76,230,000 | $-47,325,000 |
| Reconciled Depreciation | $281,000 | $156,000 | $100,000 | $89,000 |
| EBITDA (Bullshit earnings) | $-207,935,000 | $-108,274,000 | $-76,230,000 | $-47,386,000 |
| EBIT | $-208,216,000 | $-108,430,000 | $-76,330,000 | $-47,475,000 |
| Diluted Average Shares | $35,295,663 | $27,606,022 | $22,315,877 | $1,039,490 |
| Basic Average Shares | $35,295,663 | $27,606,022 | $22,315,877 | $1,039,490 |
| Diluted NI Availto Com Stockholders | $-212,184,000 | $-109,357,000 | $-76,429,000 | $-46,827,000 |
| Tax Provision | $361,000 | $355,000 | $99,000 | $0 |
| Research And Development | $170,640,000 | $96,671,000 | $69,264,000 | $33,437,000 |
| Selling General And Administration | $65,382,000 | $33,049,000 | $21,861,000 | $14,038,000 |
| Other Gand A | $28,544,000 | $13,682,000 | $11,380,000 | $14,038,000 |
| Salaries And Wages | $36,838,000 | $19,367,000 | $10,481,000 | - |
| Total Unusual Items | - | - | - | $-61,000 |
| Total Unusual Items Excluding Goodwill | - | - | - | $-61,000 |
| Gain On Sale Of Security | - | - | - | $-61,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $739,826,000 | $443,587,000 | $345,121,000 | $176,600,000 |
| Total Assets | $806,879,000 | $496,773,000 | $367,996,000 | $200,205,000 |
| Total Non Current Assets | $2,981,000 | $3,158,000 | $2,334,000 | $1,714,000 |
| Other Non Current Assets | $726,000 | $838,000 | $234,000 | $116,000 |
| Current Assets | $803,898,000 | $493,615,000 | $365,662,000 | $198,491,000 |
| Other Current Assets | $12,746,000 | $3,734,000 | $5,280,000 | $3,880,000 |
| Cash Cash Equivalents And Short Term Investments | $791,152,000 | $489,881,000 | $360,382,000 | $194,611,000 |
| Cash And Cash Equivalents | $91,145,000 | $192,434,000 | $360,382,000 | $194,611,000 |
| Prepaid Assets | - | - | $5,280,000 | $3,880,000 |
| Non Current Deferred Assets | - | - | - | - |
| Restricted Cash | - | - | - | - |
| Debt | ||||
| Total Debt | $31,023,000 | $30,000,000 | $2,101,000 | $1,334,000 |
| Long Term Debt And Capital Lease Obligation | $30,412,000 | $29,870,000 | $1,436,000 | $1,027,000 |
| Long Term Debt | $29,159,000 | $28,322,000 | - | - |
| Current Debt And Capital Lease Obligation | $611,000 | $130,000 | $665,000 | $307,000 |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $67,053,000 | $53,186,000 | $22,875,000 | $23,605,000 |
| Total Non Current Liabilities Net Minority Interest | $30,412,000 | $29,870,000 | $1,436,000 | $1,027,000 |
| Current Liabilities | $36,641,000 | $23,316,000 | $21,439,000 | $22,578,000 |
| Payables And Accrued Expenses | $23,388,000 | $15,975,000 | $14,984,000 | $18,648,000 |
| Payables | $9,018,000 | $7,948,000 | $12,629,000 | $16,162,000 |
| Accounts Payable | $9,018,000 | $7,948,000 | $12,629,000 | $16,162,000 |
| Other Non Current Liabilities | - | - | - | - |
| Derivative Product Liabilities | - | - | - | - |
| Other Current Liabilities | - | - | - | - |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $739,826,000 | $443,587,000 | $345,121,000 | $176,600,000 |
| Total Equity Gross Minority Interest | $739,826,000 | $443,587,000 | $345,121,000 | $176,600,000 |
| Stockholders Equity | $739,826,000 | $443,587,000 | $345,121,000 | $176,600,000 |
| Gains Losses Not Affecting Retained Earnings | $965,000 | $289,000 | $0 | - |
| Other Equity Adjustments | $965,000 | $289,000 | - | - |
| Retained Earnings | $-510,186,000 | $-298,002,000 | $-188,645,000 | $-112,216,000 |
| Preferred Stock Equity | - | - | - | $2,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $37,890,616 | $29,865,030 | $24,360,233 | $17,403,315 |
| Share Issued | $37,890,616 | $29,865,030 | $24,360,233 | $17,403,315 |
| Tangible Book Value | $739,826,000 | $443,587,000 | $345,121,000 | $176,600,000 |
| Invested Capital | $768,985,000 | $471,909,000 | $345,121,000 | $176,600,000 |
| Working Capital | $767,257,000 | $470,299,000 | $344,223,000 | $175,913,000 |
| Capital Lease Obligations | $1,864,000 | $1,678,000 | $2,101,000 | $1,334,000 |
| Total Capitalization | $768,985,000 | $471,909,000 | $345,121,000 | $176,600,000 |
| Additional Paid In Capital | $1,249,043,000 | $741,297,000 | $533,764,000 | $288,814,000 |
| Capital Stock | $4,000 | $3,000 | $2,000 | $2,000 |
| Common Stock | $4,000 | $3,000 | $2,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,253,000 | $1,548,000 | $1,436,000 | $1,027,000 |
| Current Capital Lease Obligation | $611,000 | $130,000 | $665,000 | $307,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,642,000 | $7,211,000 | $5,790,000 | $3,623,000 |
| Current Accrued Expenses | $14,370,000 | $8,027,000 | $2,355,000 | $2,486,000 |
| Net PPE | $2,255,000 | $2,320,000 | $2,100,000 | $1,598,000 |
| Gross PPE | $2,255,000 | $2,320,000 | $2,345,000 | $1,743,000 |
| Other Properties | $2,255,000 | $2,320,000 | $1,930,000 | $1,430,000 |
| Other Short Term Investments | $700,007,000 | $297,447,000 | $0 | - |
| Accumulated Depreciation | - | $-401,000 | $-245,000 | $-145,000 |
| Leases | - | $566,000 | $0 | - |
| Machinery Furniture Equipment | - | $586,000 | $415,000 | $313,000 |
| Properties | - | $0 | $0 | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-181,326,000 | $-94,431,000 | $-73,551,000 | $-42,403,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-180,393,000 | $-93,926,000 | $-73,462,000 | $-42,252,000 |
| Cash Flow From Continuing Operating Activities | $-180,393,000 | $-93,926,000 | $-73,462,000 | $-42,252,000 |
| Operating Gains Losses | - | - | - | $61,000 |
| Investing Activities | ||||
| Capital Expenditure | $-933,000 | $-505,000 | $-89,000 | $-151,000 |
| Investing Cash Flow | $-394,299,000 | $-292,332,000 | $-89,000 | $-151,000 |
| Cash Flow From Continuing Investing Activities | $-394,299,000 | $-292,332,000 | $-89,000 | $-151,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $450,112,000 | $187,302,000 | $199,078,000 | $53,500,000 |
| Financing Cash Flow | $473,407,000 | $218,314,000 | $239,379,000 | $148,978,000 |
| Cash Flow From Continuing Financing Activities | $473,407,000 | $218,314,000 | $239,379,000 | $148,978,000 |
| Net Common Stock Issuance | $450,112,000 | $187,302,000 | $199,078,000 | $53,500,000 |
| Common Stock Issuance | $450,112,000 | $187,302,000 | $199,078,000 | $53,500,000 |
| Net Other Financing Charges | - | $-1,393,000 | - | $95,259,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Issuance Of Debt | $0 | $28,988,000 | $0 | - |
| Interest Paid Supplemental Data | $2,795,000 | $198,000 | $0 | - |
| End Cash Position | $91,387,000 | $192,672,000 | $360,616,000 | $194,788,000 |
| Beginning Cash Position | $192,672,000 | $360,616,000 | $194,788,000 | $88,213,000 |
| Changes In Cash | $-101,285,000 | $-167,944,000 | $165,828,000 | $106,575,000 |
| Proceeds From Stock Option Exercised | $23,295,000 | $3,417,000 | $40,301,000 | $219,000 |
| Net Issuance Payments Of Debt | $0 | $28,988,000 | $0 | - |
| Net Long Term Debt Issuance | $0 | $28,988,000 | $0 | - |
| Long Term Debt Issuance | $0 | $28,988,000 | $0 | - |
| Net Investment Purchase And Sale | $-393,366,000 | $-291,827,000 | $0 | - |
| Sale Of Investment | $456,219,000 | $94,800,000 | $0 | - |
| Purchase Of Investment | $-849,585,000 | $-386,627,000 | $0 | - |
| Net PPE Purchase And Sale | $-933,000 | $-505,000 | $-89,000 | $-151,000 |
| Purchase Of PPE | $-933,000 | $-505,000 | $-89,000 | $-151,000 |
| Change In Working Capital | $3,526,000 | $3,231,000 | $-2,953,000 | $2,125,000 |
| Change In Other Current Liabilities | $186,000 | $-495,000 | $-54,000 | $-319,000 |
| Change In Payables And Accrued Expense | $12,262,000 | $2,155,000 | $-1,733,000 | $2,028,000 |
| Change In Accrued Expense | $11,192,000 | $6,836,000 | $2,008,000 | $1,502,000 |
| Change In Payable | $1,070,000 | $-4,681,000 | $-3,741,000 | $526,000 |
| Change In Account Payable | $1,070,000 | $-4,681,000 | $-3,741,000 | $526,000 |
| Change In Prepaid Assets | $-8,922,000 | $1,571,000 | $-1,166,000 | $352,000 |
| Other Non Cash Items | $2,163,000 | $533,000 | $290,000 | $211,000 |
| Stock Based Compensation | $34,340,000 | $16,815,000 | $5,530,000 | $2,089,000 |
| Amortization Of Securities | $-8,519,000 | $-5,304,000 | $0 | - |
| Depreciation Amortization Depletion | $281,000 | $156,000 | $100,000 | $89,000 |
| Depreciation And Amortization | $281,000 | $156,000 | $100,000 | $89,000 |
| Net Income From Continuing Operations | $-212,184,000 | $-109,357,000 | $-76,429,000 | $-46,827,000 |
| Income Tax Paid Supplemental Data | - | $299,000 | $112,000 | $0 |
| Change In Other Current Assets | - | - | $0 | $64,000 |
| Gain Loss On Investment Securities | - | - | - | $61,000 |
| Repayment Of Debt | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Sale Of PPE | - | - | - | - |
| Change In Other Working Capital | - | - | - | - |
| Depreciation | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-23